nicardipine has been researched along with Cancer of Esophagus in 4 studies
Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nicardipine-induced bradycardia has been reported in experimental animals but not in clinical patients." | 7.71 | Profound sinus bradycardia after intravenous nicardipine. ( Ando, H; Arima, H; Katsuya, H; Morishima, T; Sobue, K; Tanaka, S, 2002) |
| "Esophageal achalasia (EA) is a rare disease in man and animals and there are many discussions on its higher risk of esophageal cancer." | 5.30 | High incidence of esophageal cancer in esophageal achalasia by the oral administration of N-amyl-N-methylnitrosamine and its prevention by nicardipine hydrochloride in mice. ( Baskar, R; Fukuda, K; Hongyo, T; Kurooka, M; Li, LY; Matsuda, H; Miyata, M; Nakajima, H; Nomura, T; Sutoh, K, 1998) |
| "Nicardipine-induced bradycardia has been reported in experimental animals but not in clinical patients." | 3.71 | Profound sinus bradycardia after intravenous nicardipine. ( Ando, H; Arima, H; Katsuya, H; Morishima, T; Sobue, K; Tanaka, S, 2002) |
| "Esophageal achalasia (EA) is a rare disease in man and animals and there are many discussions on its higher risk of esophageal cancer." | 1.30 | High incidence of esophageal cancer in esophageal achalasia by the oral administration of N-amyl-N-methylnitrosamine and its prevention by nicardipine hydrochloride in mice. ( Baskar, R; Fukuda, K; Hongyo, T; Kurooka, M; Li, LY; Matsuda, H; Miyata, M; Nakajima, H; Nomura, T; Sutoh, K, 1998) |
| "Nicardipine and diltiazem were used as the calcium-channel blockers, which were given orally or intravenously." | 1.27 | [Cancer chemotherapy combined with a calcium antagonist in patients with hematologic malignancies and solid tumors resistant to standard chemotherapy]. ( Sampi, K, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akazawa, S | 1 |
| Honda, T | 1 |
| Sampi, K | 2 |
| Futatsuki, K | 1 |
| Kurooka, M | 1 |
| Hongyo, T | 1 |
| Nakajima, H | 1 |
| Baskar, R | 1 |
| Li, LY | 1 |
| Fukuda, K | 1 |
| Sutoh, K | 1 |
| Miyata, M | 1 |
| Matsuda, H | 1 |
| Nomura, T | 1 |
| Arima, H | 1 |
| Sobue, K | 1 |
| Tanaka, S | 1 |
| Morishima, T | 1 |
| Ando, H | 1 |
| Katsuya, H | 1 |
4 other studies available for nicardipine and Cancer of Esophagus
| Article | Year |
|---|---|
[Combination chemotherapy of nicardipine and vindesine sulfate, cis-diammine dichloroplatinum (II) for patients with advanced esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Carcinoma, Squamous Cell; | 1984 |
High incidence of esophageal cancer in esophageal achalasia by the oral administration of N-amyl-N-methylnitrosamine and its prevention by nicardipine hydrochloride in mice.
Topics: Administration, Oral; Animals; Calcium Channel Blockers; Carcinogens; Carcinoma, Squamous Cell; Esop | 1998 |
Profound sinus bradycardia after intravenous nicardipine.
Topics: Aged; Arrhythmia, Sinus; Bradycardia; Calcium Channel Blockers; Electrocardiography; Esophageal Neop | 2002 |
[Cancer chemotherapy combined with a calcium antagonist in patients with hematologic malignancies and solid tumors resistant to standard chemotherapy].
Topics: Acute Disease; Administration, Oral; Antibiotics, Antineoplastic; Diltiazem; Drug Therapy, Combinati | 1987 |